Blue­print maps plans for $150M raise; Glax­o­SmithK­line cre­ates dis­cov­ery pact with Warp Dri­ve

→ Blue­print Med­i­cines $BPMC has filed to raise $150 mil­lion in a new stock of­fer­ing. Most of the new mon­ey is be­ing ear­marked for up­com­ing clin­i­cal tri­als of its pipeline drugs. And the com­pa­ny says it will add to the $268 mil­lion al­ready in re­serves at the end of 2016, stretch­ing its run­way to the mid­dle of 2019.

→ Cam­bridge, MA-based Warp Dri­ve Bio has set up a dis­cov­ery deal with Glax­o­SmithK­line, cre­at­ing a cus­tom DNA-tagged SMART li­brary that GSK will build and screen against a set of ‘un­drug­gable’ tar­gets re­lat­ed to dis­eases of high un­met med­ical need. Among the Warp Dri­ve tar­gets are RAS, SHP2 and Cbl-b. “This unique col­lab­o­ra­tion with GSK of­fers an in­valu­able op­por­tu­ni­ty to com­bine two pow­er­ful plat­forms to cre­ate an un­prece­dent­ed li­brary of up to 200 mil­lion di­verse SMART com­pounds for the dis­cov­ery of lead chem­i­cal mat­ter against a set of cur­rent­ly-in­ac­ces­si­ble tar­gets,” said Alan Rig­by, Ph.D., chief sci­en­tif­ic of­fi­cer of Warp Dri­ve Bio.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER